Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01355718
Recruitment Status : Completed
First Posted : May 18, 2011
Last Update Posted : August 11, 2014
Information provided by (Responsible Party):
Novo Nordisk A/S

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 2013
  Actual Study Completion Date : March 2013